BRAIN CANCER

HER2 Breast Cancer

BREAST CANCER

Bladder Cancer

Prostate Cancer

Renal Cell Carcinoma

GENITOURINARY CANCERS

Liquid Biopsies

GENOMIC TESTING

Colorectal Cancer

GIST

Gastric Cancer

GI CANCERS

Cervical Cancer

Endometrial Cancer

Ovarian Cancer

GYNECOLOGIC CANCERS

HEAD & NECK CANCERS

Bone Marrow & Stem Cell Transplant

HEMATOLOGY

CAR T-Cell Therapy

IMMUNOTHERAPY

Chronic Lymphocytic Leukemia

Chronic Myeloid Leukemia

LEUKEMIAS

Biomarker-Driven Lung Cancer

EGFR+ Lung Cancer

MET-Targeted Therapy

Small Cell Lung Cancer

LUNG CANCER

DLBCL

Follicular Lymphoma

Mantle Cell Lymphoma

LYMPHOMAS

MPNs

MULTIPLE MYELOMA

NTRK GENE FUSIONS

SARCOMA

Melanoma

SKIN CANCERS

THYROID CANCERS

NEWS

Special Reports

All News

FDA Briefs

Oncology Icons

The Targeted Pulse

Voices from the Field

CONFERENCES

Conference Coverage

Conference Listing

Data Dialogue with the Oncology Brothers

MEDIA

All Videos

Case-Based Peer Perspectives

Evolving Paradigms in Oncology

Expert Perspective Virtual Tumor Board

Interviews

Investigator Perspectives

Medical World News

Pivotal Practice Views with the Oncology Brothers

Podcasts

Speaking Out

PUBLICATIONS

All Publications

Evolving Paradigms

Peers & Perspectives in Oncology

Targeted Therapies in Oncology

CASE-BASED ROUNDTABLE

PARTNERS

RESOURCES

CME/CE

Clinical Trials

Events

Precision Medicine Perspectives

Press Releases

Treatment Resources

SUBSCRIBE

Targeted Oncology provides news, videos, and reviews on the rapidly evolving world of targeted therapies and immunotherapy for oncologists treating patients in a community setting.

About Us

Advertise

Contact Us

CureToday.com

CancerNetwork.com

OncLive.com

OncNursingNews.com

Do Not Sell My Information

Privacy

Terms & Conditions

Editorial Board

Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways

Facebook

Linkedin

YouTube

Instagram

Featured Clinical Focus

BTK Inhibitors: In-Focus

Bone Marrow & SCT

EGFR-Positive Lung Cancer

Lung Cancer

Multiple Myeloma

Thyroid Cancers

Clinical Focus

Brain Cancer

Breast Cancer

Gastrointestinal Cancer

Genitourinary Cancers

Gynecologic Cancers

Head & Neck Cancers

Hematology

Leukemias

Lymphomas

Sarcoma

Skin Cancers

Spotlight

1rem

View

Emerging Treatment Landscape in MPNs: From Current Practice to Emerging Therapies

Video Series

Case Based Peer Perspectives

A 68-Year-Old Woman Diagnosed With Primary Myelofibrosis

Videos

An expert discusses the emerging treatment landscape in myeloproliferative neoplasms (MPNs), focusing on the transition from current practices to emerging therapies.

An expert discusses the case of a 68-year-old woman diagnosed with primary myelofibrosis.

An expert discusses what stands out most about this patient’s molecular profile and how these insights enhance the diagnostic approach in myeloproliferative neoplasms (MPNs).

Molecular Profiling in MPNs: Enhancing Diagnostic Insights

An expert discusses how advances in JAK V617F monitoring have improved the assessment of disease status and guided treatment decisions and how risk assessment tools have transformed the ability to optimize treatment selection in patients with myeloproliferative neoplasms (MPNs).

JAK V617F Monitoring and Risk Assessment Tools: Optimizing Treatment Decisions in MPN

An expert discusses how the positive efficacy findings from the phase 3 RESPONSE trial, showing high rates of hematocrit control and spleen response with ruxolitinib vs standard therapy in hydroxyurea-resistant/intolerant polycythemia vera (PV), have enhanced the treatment approach for patients with inadequate response to hydroxyurea.

Treatment Insights From RESPONSE: Ruxolitinib Therapy in Hydroxyurea-Resistant/Intolerant Disease

A 68-Year-Old Woman Diagnosed With Primary Myelofibrosis

EP: 1.A 68-Year-Old Woman Diagnosed With Primary Myelofibrosis

EP: 2.Molecular Profiling in MPNs: Enhancing Diagnostic Insights

EP: 3.JAK V617F Monitoring and Risk Assessment Tools: Optimizing Treatment Decisions in MPN

EP: 4.Treatment Insights From RESPONSE: Ruxolitinib Therapy in Hydroxyurea-Resistant/Intolerant Disease